A few weeks back, in the San Francisco Bay Area, I joined other BrightInsight executives at the 2023 Deloitte Technology Fast 500™ event. Now in its 29th year, the Deloitte Technology Fast 500™ provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies—both public and private—in North America. The 2023 Technology Fast 500 award winners were selected based on percentage fiscal year revenue growth from 2019 to 2022.
BrightInsight ranked at number 307 with 431% revenue growth underscoring our position as the de facto digital health platform for the world’s top biopharma and medtech companies. This is the second time BrightInsight has earned this elite honor, marking our sustained growth over time. The significant growth we achieved is testament to our market-leading technology and our team’s proven ability to deliver digital solutions with real-world impact.
BrightInsight ranked 56th out of the 94 Bay Area companies that appeared on the list, and 174th of the 310 software and services companies.
We made important strides this year, including significant investment and the launch of key technical advances in our platform, several global launches of clients’ patient companion apps and new projects for existing customers.
Our continued growth is validation that many of the world’s leading biopharma and medtech companies are partnering with BrightInsight to help them achieve their digital health goals and initiatives, in order to bring regulated solutions to market quickly in a compliant manner, including drug companion apps, Software as a Medical Device (SaMD), algorithms and more, which will ultimately add value to their therapies and devices, and enhance the patient journey.
I extend my gratitude and congratulations to our whole team for this important achievement. Our momentum continues to build.